#USA #Chicago #Cancer Research #AACR 2025 #Tsingke Biotech

Tsingke's Impact at AACR 2025

The AACR Annual Meeting held in April 2025 in Chicago marked a pivotal gathering for leaders in the oncology research community. Tsingke Biotech was proud to showcase its advancements in integrated synthesis solutions designed to enhance global cancer research. With an array of offerings showcased at Booth #3255, Tsingke attracted attention for its innovative approach, which bridges early-stage discovery and preclinical development.

The Role of Tsingke Biotech in Oncology Research

At the heart of Tsingke’s mission is the support for professionals in biotech companies and academic institutions. By providing a comprehensive synthesis and expression service portfolio, Tsingke aids researchers at crucial stages of their work. The company’s capabilities encompass entire workflows, from molecular design to functional validation, necessary for advancing therapeutic solutions.

High-Throughput Nucleic Acid Synthesis

One of the standout features of Tsingke’s platform is its high-throughput nucleic acid synthesis capability. The company specializes in generating custom DNA and RNA oligonucleotides, including siRNA and ASO. These are essential for complex modifications such as locked nucleic acids (LNA), phosphorothioates, and dual-labeled probes, along with high-quality primers and probes suitable for qPCR and NGS applications. Tsingke is committed to facilitating researchers with tools that streamline their workflows.

mRNA Synthesis Services

In addition to nucleic acids, Tsingke offers mRNA synthesis through a supply of high-purity materials. This includes IVT template synthesis complete with necessary modifications such as 5’/3’ caps and poly(A) tails. Noteworthy is their provision of high-purity enzymes, capping reagents, and custom buffers. This aspect of Tsingke’s service is designed to support lipid nanoparticle (LNP) formulation workflows, which are crucial in developing mRNA-based therapeutics.

Advanced Protein Expression Tools

The biopharmaceutical space can also greatly benefit from Tsingke's protein expression services. Tsingke provides essential tools for antibody development, including gene synthesis, vector construction, and validation. Their rapid expression services using HEK293 and CHO systems ensure that critical projects can maintain momentum.

Support for Novel Therapies

As the landscape of cancer therapies evolves, Tsingke offers custom RD support tailored to innovative approaches. Their offerings include sgRNA libraries, gene editing tools, and RNAi constructs, all imperative for researchers pursuing cutting-edge treatments. By enabling biotech companies and academic researchers to harness these resources, Tsingke plays a crucial role in the translation of research into viable treatments.

Building a Global Synthesis Platform

Tsingke is steadfast in its aim to foster innovation in cancer research and treatment through a global synthesis platform. Their approach supports an entire ecosystem crucial for advancements in cancer therapeutics, facilitating collaboration between academia and industry leaders.

The company invites those interested in exploring custom solutions to connect directly, showcasing its dedication to enhancing the cancer research landscape. Visit Tsingke at www.tsingke.com or reach out via email for more information on how they can assist you in your research needs.

By aligning with global leaders at AACR 2025, Tsingke Biotech reaffirms its position at the forefront of cancer research innovation, providing the tools required to accelerate the journey from lab to clinic.